The US Food and Drug Administration needs more tailored enforcement authority to streamline opioid Risk Evaluation and Mitigation Strategy administration, a federal watchdog argued.
A review of the FDA’s handling of the REMS for extended-release-long-acting opioid and transmucosal immediate-release fentanyl (TIRF) products by the...




